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Disease modifying anti‑rheumatic drugs (DMARDs) were developed to treat joint inflammation. There 
is growing evidence that anti‑inflammatory drugs prevent major cardiovascular events (MACE). The 
aim of this systematic review and meta‑analysis was to examine whether DMARDs reduce the risk of 
MACE. A systematic literature search was performed to identify randomized controlled trials (RCTs) 
testing the effect of DMARDs on cardiovascular events. The primary outcome was MACE defined as 
the first occurrence of non‑fatal myocardial infarction (MI), non‑fatal stroke or cardiovascular death. 
Secondary outcomes were myocardial infarction or stroke alone and all‑cause mortality. Safety 
was assessed by fatal or life threatening infection. Meta‑analyses were performed using random 
effect models and reported as risk ratios (RR) and 95% confidence intervals (CI). Study quality and 
publication bias were assessed using the Cochrane Collaboration’s tool for assessing risk of bias and 
funnel plots. Twelve RCTs involving 18,056 participants testing three different DMARDs subclasses 
(Tumor Necrosis Factor inhibitors—4 trials; Janus Kinase inhibitors—5 trials; Interleukin inhibitors—3 
trials) were included. Meta‑analysis suggested that none of the DMARD subclasses had any effect on 
MACE, MI alone, stroke alone, risk of fatal or life threatening infection or death. Risk of bias was high, 
low and unclear in five, six and one studies respectively. Funnel plots suggested a low possibility of 
publication bias. This meta‑analysis suggests that DMARDs do not affect the incidence of MACE. More 
trials are needed for firm conclusions.
Inflammation is strongly implicated in atherosclerosis progression and associated  thrombosis1,2. High circulating 
concentrations of inflammatory biomarkers, such as C-reactive protein, are associated with a high incidence 
of cardiovascular (CV) events and have been used to identify people for preventative therapy, such as statin 
 prescription3–5. The Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) showed that 
people randomly allocated to a monoclonal antibody blocking interleukin-1β (canakinumab) had a reduced 
incidence of major cardiovascular events (MACE, i.e. myocardial infarction (MI), stroke or cardiovascular death) 
compared to those allocated to  placebo6. This finding suggests that other anti-inflammatory drugs may also have 
a therapeutic role in prevention of cardiovascular events.
Disease modifying anti-rheumatic drugs (DMARDs) were developed primarily to treat joint  inflammation7–9. 
Due to their powerful anti-inflammatory effects, it is plausible that DMARDs may also prevent cardiovascular 
events. Inhibition of cytokines, such as tumor necrosis factor (TNF) and interleukins (ILs), and janus kinase 
(JAK) have been reported to limit inflammatory mechanisms implicated in athero-thrombosis through studies in 
animal  models10–12. Most commonly prescribed biologic and targeted synthetic DMARDs such as TNF-alpha (α) 
inhibitors, IL-1 beta (β) & IL-12/23 inhibitors and JAK-1/2 inhibitors have been tested in randomized controlled 
trials within a variety of different populations that are at risk of MACE, such as people with rheumatoid arthritis 
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and  psoriasis13–17. Prior clinical trials report both  positive6 and negative  findings18,19 on the effect of DMARDs 
on MACE. Further, there is no consensus on whether all DMARDs are effective in reducing MACE, with prior 
systematic reviews reporting both  positive20,21 and  negative22,23 findings by comparing between biologic and 
conventional synthetic DMARDs and also within subclasses of biologic DMARDs.
Prior meta-analyses have been restricted to specific disease populations, such as people with  psoriasis24 or 
rheumatoid  arthritis25, limiting the power to test the effect of DMARDs on MACE. Previous systematic reviewers 
have also incorporated observational data together with findings from randomized controlled trials limiting the 
ability to interpret findings due to lack of comparison to placebo controlled  groups22,25–31. Furthermore, rand-
omized trials specifically examining the effect of DMARDs on MACE have been published since these previous 
meta-analyses were reported; meaning that more up to date data are available but have not been systematically 
 appraised6,14,32,33. In view of this, and past lack of consensus and limitations of previous systematic reviews, 
there is a need for an up to date comprehensive meta-analyses. This systematic review and meta-analysis aimed 
to provide an up to date test of whether DMARDs reduce the risk of cardiovascular events, using data from all 
available randomized controlled trials.
Methods
Search strategy and eligibility criteria. The systematic review was performed according to the Preferred 
Reporting the Items for Systematic Review and Meta-Analysis (PRISMA) statement and registered in the PROS-
PERO database (Registration Number: CRD42020166140). The literature search was conducted by one author 
(ST). The databases PubMed, Cochrane Central Register for Controlled Trials and Scopus were searched on 
12th January 2021. The search strategy included the synonyms or similar terms of "Cardiovascular events" AND 
"DMARDs" AND “Randomized controlled trials” (See supplementary material for full search terms). No date 
and language restriction were applied. This review was restricted to biologic and targeted synthetic DMARDs 
that target TNF-α, IL-1β, IL-12/23 and JAK1/2. To be eligible for inclusion, studies had to adopt: A randomized 
controlled design; test drugs in the DMARD class that target TNF, IL or JAK; include a placebo control group; 
and either reported the number of CV events (at least one of MACE, MI alone or stroke) or all-cause mortal-
ity. Both full text and abstracts of studies meeting entry criteria were included as long as minimum data were 
available either within the report, within the clinical trial registration entry or by contacting the corresponding 
author. Minimum data included DMARD tested, dose used, mean age of patients in control and intervention 
groups, duration of treatment and reported number of MACE, MI, stroke or death in both intervention and 
control groups. Exclusion criteria included trials adopting an open label or non-randomized design and studies 
where minimum data were not available. Included articles were identified by one author (ST) and reviewed by 
two more authors (JP, SMK) to confirm that they met entry criteria. Any discrepancies were resolved by discus-
sion with another author (JM).
Data extraction and outcomes. Data were extracted on a customized spreadsheet by four authors (ST, 
JP, SMK, JG). Any inconsistencies were resolved through discussion with another independent author (JM). 
The primary outcome of this study was MACE incidence, defined as the first occurrence of any non-fatal MI 
or non-fatal stroke or cardiovascular death. Death occurring due to MI, stroke or any other cardiovascular 
related conditions was defined as cardiovascular death. Secondary outcomes were the incidence of MI, stroke 
or cardiovascular death alone, or all-cause mortality. Safety was assessed through the incidence of fatal or life 
threatening infection or infections requiring hospital admission. Outcome data were reported relative to the 
number of patients in whom results were reported for. The following information was also extracted from the 
included trials: Primary diagnosis of the population, cardiovascular risk factors, sample size for both control 
and intervention groups, name, dose and type of DMARD drug tested, entry and exclusion criteria for the trial, 
duration of treatment period, age, sex, history of MI and stroke and use of DMARDs other than the drug being 
tested (including TNF-α or receptor inhibitors, IL-1β or IL-12/23 inhibitors and JAK-1/2 inhibitors) at baseline.
Quality assessment. Three authors independently assessed the risk of bias of all included studies using 
the Cochrane Collaboration’s tool which assessed key aspects of the reports including guideline definitions for 
included patient groups, random sequence generation, blinding of participants and assessors, statistical sam-
ple size estimate, reporting the number of patients who completed the study, percentage of patients who had 
incomplete data, a clear primary outcome, intent-to-treat analysis and other  biases34. Any inconsistencies were 
resolved through discussion between the authors until a consensus was reached. Each aspect was rated as low, 
high or unclear risk of bias. Each trial was then given an overall rating of risk of bias. If any aspect of the trial 
was considered high (or unclear) risk of bias this overall rating was given. A low risk of bias rating required all 
aspects to be given this assessment (Supplementary Table 14).
Data analysis. Meta-analyses were performed for any of the primary or secondary outcomes where data 
were available from at least three trials. The main analyses pooled data from individual DMARD classes, specifi-
cally, TNF-α inhibitors, JAK-1/2 inhibitors or IL-1β, IL-12/23 inhibitors, where data for one or more outcomes 
were available from a minimum of three trials. In trials that had no events in either one of the groups, ‘zero’ event 
was imputed by adding one event equally to all groups in the study. Due to the small number of eligible stud-
ies, meta-analyses were performed using the inverse variance method with random effects models and applied 
Sidik-Jonkman method with Hartung‐Knapp modification to estimate the between-study variance (tau2)35. This 
estimator uses the Q-profile method to provide a conservative and broader CI to minimize the risk of false 
positive results. Random effects analyses were preselected with an anticipation of high heterogeneity between 
studies. Statistical heterogeneity between studies was assessed using the  I2 statistic and interpreted as low (0 to 
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49%), moderate (50 to 74%) or high (75 to 100%)36. The contribution of each study to the pooled estimates of 
outcome measures were assessed by performing leave-one-out sensitivity analyses where individual studies were 
excluded to inspect if they influenced the overall estimated effects. Publication bias was assessed by funnel plots 
comparing the overall effect size of each study to the standard error of its log-transformed  effect37. Meta-analysis 
was conducted using ‘meta’ package and sensitivity analysis was performed using ‘dmetar’ package of R software 
version 3.4.4. All statistical tests were two-sided and p value of ≤ 0.05 was considered significant.
Results
Included trials and participants. The literature search identified 4043 unique records of which 12 trials 
including a total of 18,056 participants ultimately met the inclusion criteria (Fig. 1). Four trials tested TNF-α 
inhibitors (Infliximab or Certolizumab pegol) or a TNF receptor inhibitor (Etanercept) in 3612  participants18,38–40. 
Five trials tested JAK-1/2 inhibitors (Upadacitinib or Baricitinib or filgotinib) in 2819  people14,33,41–43. Three tri-
als tested IL inhibitors (Briakinumab or Canakinumab or Anakinra) in 11,625  participants6,15,44. Three trials 
were conducted in the  USA38,39,44 and the other nine trials recruited people from multiple  countries6,14,15,18,33,40–43. 
The primary diagnoses and risk factors of the participants involved in the included trials were heterogeneous 
(Supplementary Table 1 and 2). People with rheumatoid arthritis were included in trials testing  Etanercept39, 
 Upadacitinib14,33,  Baricitinib41,42, Certolizumab  pegol40 and  Filgotinib43. People with heart failure were included 
in trials testing  Infliximab38 and  Etanercept18. People with psoriasis were included in trials testing  Briakinumab15 
and MI patients were included in trials testing  Canakinumab6 and  Anakinra44. The medical management of the 
included participants, such as prescription of statins, anti-platelet and anti-hypertensive medications, was poorly 
and variably reported (Table 1). The follow-up periods in the trials ranged between 12 and 54 weeks (Table 1). 
Eligibility criteria, follow-up and study centers are shown in Supplementary Table 2. The outcomes of included 
studies are shown in Table 2.  
MACE
Ten studies reported the effect of a DMARD on the incidence of  MACE6,14,15,33,39–44. Two trials reported that 
Briakinumab and Baricitinib increased the incidence of  MACE15,41. Seven trials reported that Upadacitinib, 
Anakinra, Baricitinib, Filgotinib and Certolizumab pegol had no effect on  MACE14,33,39,40,42–44 and one trial 
reported a significant reduction in MACE with  Canakinumab6.
Figure 1.  Preferred Reporting Items of Systematic Review and Meta-analyses (PRISMA) flow diagram. A total 
of 4043 studies were screened and 12 Randomized trials were included for analyses.
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(weeks) Age (Years) Male gender (%)
Previous history 
of CHF (%)










Tumor necrosis factor inhibitors
Chung et al., 
2003
Placebo (n = 49)
28
60 ± 12.0 76.0 100.0 No NR NR 84.0*
Inflximab 5 mg/




62 ± 13.0 84.0 100.0 No NR NR 80.0*
Emery et al., 
 2015b
Placebo (n = 219)
52
51.3 ± 13.2 20.1 NR NR NR NR NR
Certolizumab 
pegol (n = 660) 50.5 ± 13.6 24.4 NR NR NR NR NR
Mann et al., 
 2004a
Placebo (n = 682)
24
64.6 ± 10.8 76.0 100.0 NR NR NR 83.5*
Etanercept QW 
(n = 375) 64.8 ± 10.3 77.0 100.0 NR NR NR 83.0*
Etanercept BIW 
(n = 683) 62.95 ± 11.2 79.0 100.0 NR NR NR 82.0*
Etanercept TIW 
(n = 308) 62.4 ± 11.0 81.0 100.0 NR NR NR 79.0*
Weisman et al., 
 2007d
Placebo (n = 269)
16
59.3 (23–85) 21.9 32.0 No NR NR NR
Etanercept 




Placebo (n = 221)
12
56 ± 12.2 25.0 NR No NR NR NR
Upadacitinib 
15 mg(n = 221) 55.3 ± 11.5 18.0 NR No NR NR NR
Upadacitinib 
30 mg(n = 219) 55.8 ± 11.3 21.0 NR No NR NR NR
Genovese et al., 
2018




56.3 ± 11.3 16.0 NR NR NR NR NR
Upadacitinib 
30 mg(n = 165) 57.3 ± 11.6 16.0 NR NR NR NR NR
Genovese et al., 
2016
Placebo (n = 176)
24
56 ± 11.0 18.0 NR Yes NR NR NR
Baricitinib 2 mg 
(n = 174) 55 ± 11.0 21.0 NR Yes NR NR NR
Baricitinib 4 mg 
(n = 177) 56 ± 11.0 16.0 NR Yes NR NR NR
Dougados et al., 
2017
Placebo (n = 228)
12
51 ± 13.0 17.0 NR Yes NR NR NR
Baricitinib 2 mg 
(n = 229) 52 ± 12.0 20.0 NR Yes NR NR NR
Baricitinib 4 mg 
(n = 227) 52 ± 12.0 18.0 NR Yes NR NR NR
Genovese et al., 
2019
Placebo (n = 148)
24
56 ± 12.1 18.2 NR Yes NR NR NR
Filgotinib 
100 mg (n = 153) 56 ± 12.0 22.2 NR Yes NR NR NR
Filgotinib 




Placebo (n = 484)
12
45.1 ± 13.5 70.9 0.2 No NR NR NR
Briakinumab 






61.1 ± 10.0 74.1 21.6 NR 91.1 95.3 79.8**
Canakinumab 
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A meta-analysis of five trials testing JAK inhibitors in 2819 participants (RR = 0.73; 95% CI 0.22, 2.43)14,33,41–43 
and three trials testing IL inhibitors in 11,625 participants (RR = 0.94; 95% CI 0.22, 4.00)6,15,44 suggested these 
drugs did not significantly affect the relative risk of MACE with low heterogeneity between the included studies 
(Fig. 2). Leave one out sensitivity analyses found that the outcomes were consistent (Supplementary Tables 3 and 
4). Funnel plots suggested no publication bias (Supplementary Fig. 1). Insufficient trials testing TNF inhibitors 
reported MACE to qualify for meta-analysis.
MI alone. Six included trials reported the incidence of MI alone. Three trials testing Certolizumab pegol, 
Baricitinib and Anakinra reported no significant effect on the incidence of  MI40,42,44. Two trials reported that bri-
akinumab and baricitinib increased the incidence of  MI15,41. One trial reported that canakinumab significantly 
reduced the incidence of  MI6.
A meta-analysis of three trials testing the effect of JAK inhibitors in 1660 participants suggested no significant 
effect on the risk of MI (RR = 0.63; 95% CI 0.09, 4.53)14,41,42. A meta-analysis of three trials testing the effect of 
IL inhibitors in 11,625 participants suggested no significant effect on the risk of MI (RR = 0.88; 95% CI 0.58, 
1.33)6,15,44 (Fig. 3). Sensitivity analyses suggested that the results were robust (Supplementary Tables 5, 6). Fun-
nel plots suggested no publication bias in trials testing JAK inhibitors, but was noted to be asymmetrical in the 
meta-analysis on IL inhibitors (Supplementary Fig. 2). Insufficient trials testing TNF inhibitors reported MI 
alone to qualify for meta-analysis.
Stroke alone. Eight of the trials testing DMARDs and all reported no significant effect on the incidence 
of stroke  alone6,14,15,33,40–42,44. Meta-analysis of five trials testing JAK inhibitors in 2819 participants (RR = 0.58; 
95% CI 0.22, 1.50)14,33,41–43 and three trials testing IL inhibitors in 11,625 participants (RR = 0.93; 95% CI 0.78, 
1.09)6,15,44 suggested that DMARDs had no significant effect on the relative risk of stroke (Fig. 4). Sensitivity 
analyses and funnel plots showed that the findings were consistent and removal of individual trials did not 
change the overall results (Supplementary Fig. 3 and Supplementary Tables 7 and 8). Insufficient trials testing 
TNF inhibitors reported the outcome of stroke alone to qualify for a meta-analysis.
Cardiovascular death alone. A total of three trials reported cardiovascular death  alone6,15,39. One trial 
tested TNF inhibitors in 535 participants and reported 1 and 3 cardiovascular deaths in participants’ allocated 
placebo and etanercept  respectively39. Two trials tested IL inhibitors in 11,526 participants and reported 182, 319 
and 1 cardiovascular deaths in participants’ allocated placebo, canakinumab and briakinumab  respectively6,15. 
Insufficient trials reported this outcome to qualify for meta-analyses.
Death by any cause. All 12 trials reported that the DMARDs tested did not significantly affect all-cause 
 mortality6,14,15,18,33,38–44. Three trials reported no deaths in both treatment and placebo groups, therefore, the 
remaining nine trials were eligible for meta-analysis33,39,43. Meta-analyses of three trials testing TNF inhibitors 
in 3077 participants (RR = 1.09, 95% CI 0.77, 1.56)18,38,40, JAK inhibitors in 1709 participants (RR = 0.54; 95% CI 
0.04, 7.42)14,41,42 and IL inhibitors in 11,625 participants (RR = 0.86; 95% CI 0.33, 2.27) suggested that DMARDs 
did not significantly affect the relative risk of death (Fig. 5). In addition, sensitivity analyses and funnel plots sug-
gested that the results were consistent and unlikely to be subject to publication bias (Supplementary Tables 9–11 
and Supplementary Fig. 4).
Serious or severe infection. All 12 trials reported a non-significant higher incidence of serious or severe 
infections within people allocated  DMARDs6,14,15,18,33,38–44. The meta-analyses of four trials testing TNF inhibitors 
in 3612 participants (RR = 1.00; 95% CI 0.53, 1.90)6,18,38,40, five trials testing JAK inhibitors in 2819 participants 
(RR = 1.12; 95% CI 0.61, 2.07)14,33,41–43 and three trials testing IL inhibitors in 11,625 participants (RR = 0.64; 95% 
CI 0.03, 11.91)6,15,44 suggested that DMARDs did not significantly increase the relative risk of serious or severe 
infections (Supplementary Fig. 5). Sensitivity analyses suggested that the results were consistent and removal of 
individual studies did not affect the findings (Supplementary Tables 12–14). Funnel plots suggested no publica-
tion bias (Supplementary Fig. 6).
Table 1.  Baseline patient characteristics. NR, Not reported; CHF, Congestive Heart Failure. *, Angiotensin 
converting enzyme inhibitors; **, Renin angiotensin system inhibitors; ^, Clopidogrel. a Study was designed as 
two independent clinical trials. Placebo and BIW data were pooled together for analysis. b Study characteristics 







(weeks) Age (Years) Male gender (%)
Previous history 
of CHF (%)












Placebo (n = 35)
54
56 (51–65) 85.7 NR NR NR 20.0^ NR
Anakinra Once 
daily (n = 33) 53 (49–62) 72.7 NR NR NR 15.0^ NR
Anakinra twice 
daily (n = 31) 55 (45–61) 83.9 NR NR NR 13.0^ NR
6
Vol:.(1234567890)
Scientific Reports |         (2021) 11:6627  | https://doi.org/10.1038/s41598-021-86128-y
www.nature.com/scientificreports/
Table 2.  Outcome data from all included studies testing the effect of DMARDs. a CV death used for MACE 
calculation is death or hospitalization due to CHF. b MACE calculated from percentage and included heart 
failure, coronary artery disease, MI and cerebrovascular events. No individual event data was given. c Data 
taken from clinical trial page. d Placebo group is being randomized into intervention after 12 weeks. Therefore, 
we considered only data until 12 weeks. MACE, Major adverse cardiovascular events; MI, Myocardial 
infarction; CV death, Cardiovascular death; NR, Not reported.
Reference Groups Lost to follow up MACE MI Stroke Serious infections All-cause mortality
TNF inhibitors
Chung et al.  2003a
Placebo (n = 49) 0 NR NR NR 1 4
Infliximab 5 mg/kg 
(n = 50) 0 NR NR NR 3 4
Infliximab 10 mg/kg 
(n = 51) 0 NR NR NR 4 8
Emery et al.,  2015c
Placebo (n = 219) 2 2 0 2 7 1
Certolizumab pegol 
(n = 660) 1 5 2 2 20 2
Mann et al.,  2004a,*
Placebo (n = 682) 0 NR NR NR 13 77
Etanercept QW 
(n = 375) 0 NR NR NR 4 22
Etanercept BIW 
(n = 683) 0 NR NR NR 14 82
Etanercept TIW 
(n = 308) 0 NR NR NR 7 61
Weisman et al.,  2007b
Placebo (n = 269) 0 7 NR NR 10 NR
Etanercept (n = 266) 0 13 NR NR 8 NR
JAK inhibitors
Burmester et al., 2018
Placebo (n = 221) 0 0 0 0 1 0
Upadacitinib 
15 mg(n = 221) 0 0 0 0 1 0
Upadacitinib 
30 mg(n = 219) 0 1 0 1 3 0
Genovese et al.,  2018d
Placebo (n = 169) 0 0 0 0 0 0
Upadacitinib 
15 mg(n = 164) 0 1 0 1 1 0
Upadacitinib 
30 mg(n = 165) 0 1 0 0 4 1
Genovese et al., 2016
Placebo (n = 176) 0 0 0 0 5 0
Baricitinib 2 mg 
(n = 174) 0 0 0 0 4 0
Baricitinib 4 mg 
(n = 177) 0 2 1 1 6 1
Dougados et al., 2017
Placebo (n = 228) 0 2 1 1 4 2
Baricitinib 2 mg 
(n = 229) 0 0 0 0 2 0
Baricitinib 4 mg 
(n = 227) 0 0 0 0 4 0
Genovese et al., 2019
Placebo (n = 148) 1 1 0 1 2 0
Filgotinib 100 mg 
(n = 153) 1 1 1 0 3 0
Filgotinib 200 mg 
(n = 148) 1 0 0 0 1 0
IL inhibitors
Gordon et al.,  2012d
Placebo (n = 484) 0 0 0 0 5 0
Briakinumab (n = 981) 0 5 3 1 1 1
Ridker et l, 2017
Placebo (N = 3344) 0 535 292 92 342 375
Canakinumab 50 mg 
(n = 2170) 0 313 169 58 230 228
Canakinumab 150 mg 
(n = 2284) 0 320 159 63 258 238
Canakinumab 300 mg 
(n = 2263) 4 322 174 51 265 239
Abbate et al.,  2020c
Placebo (n = 35) 0 3 1 1 5 1
Anakinra OD (n = 33) 0 2 1 1 3 0
Anakinra TD (n = 31) 0 1 1 0 6 0
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Figure 2.  Effect of DMARDs on major cardiovascular events.
Figure 3.  Effect of DMARDs on myocardial infarction alone.
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Risk of bias. Overall, six studies had a low risk of  bias6,14,38,41,42,44, one study had an unclear risk of  bias15 and 
the remaining five studies had a high risk of  bias18,33,39,40,43. Limitations noted included the absence of intent-
to-treat  analyses18,33,39,40,43 and not reporting the primary diagnosis of  patients15 (Supplementary Table 15 and 
Table 3). Funnel plots suggested no publication bias (Supplementary Figs. 1, 2, 3, 4 and 6).
Discussion. The main finding of this meta-analysis was that the three DMARD drug classes tested had no 
significant effect on the incidence of MACE, MI alone, stroke alone and mortality and the findings were robust 
in sensitivity analyses. One of the included trials, testing the IL inhibitor Canakinumab, reported a significant 
reduction in MACE but this finding could not be replicated in the meta-analysis which included all IL inhibitor 
trials  identified6. It should be acknowledged however that the analyses are limited by the number of available 
trials and heterogeneity of the included populations and further trials are needed for robust conclusions. It was 
not possible to perform meta-analyses for the outcome of cardiovascular related mortality alone as this was 
infrequently reported.
The recent European League Against Rheumatism (EULAR) task force recommendations suggested that there 
was no increase in MACE or cancer but an increased risk of infection with the use of biological (b)DMARDs as 
compared with conventional synthetic (cs)DMARDs45. The meta-analysis suggested that IL inhibitors did not 
have any effect on the incidence of MACE or the risk of serious or severe infections similar to the current study. 
These findings suggest that DMARDs may be safe to use, although longer trials are needed. Many of the included 
trials were very short meaning conclusions on safety should be guarded.
Most of the included trials did not examine cost effectiveness. Data from the Finnish registry suggested that 
bDMARDs were not cost-effective due to a high incremental cost effectiveness ratio (ICER)46. It should be noted 
that the cost effectiveness were calculated for the treatment of rheumatoid arthritis patients. This is therefore not 
relevant to its effects in reducing MACE. A previous systematic review suggested that TNF inhibitors were cost 
effective when applying a threshold of 50,000 Euro per Quality adjusted life years (QALY) as a treatment of joint 
 inflammation47. Further, cost-effectiveness of bDMARDs have been shown to be superior to csDMARDs when 
analysed using the number needed to treat (NNT)  method48. With respect to the MACE, the CANTOS trial was 
the only large scale trial focused on secondary prevention of recurrent cardiovascular events and was estimated 
Figure 4.  Effect of DMARDs on stroke alone.
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to increase QALY by 0.13 for a cost of $832,000, yielding an ICER of 6.4 million per QALY gained. Based on 
that trial Canakinumab was not considered cost-effective. Targeted use of DMARDs, particularly if they can be 
offered at a lower cost might lead to a cost-effective treatment but this remains to be  shown49.
The findings of this meta-analysis should be interpreted after considering a number of limitations. The 
number of included trials was small limiting the statistical power. Five trials had a high risk of  bias18,33,39,40,43 due 
to failure to follow intent-to-treat principles and other methodological weaknesses. The participants included 
were noted to have heterogeneous diagnoses which complicates the interpretation of the findings. Only one 
risk of bias assessment was used based on the Cochrane collaborative tool. The Grading of Recommendations, 
Assessment, Development and Evaluation (GRADE) criteria were not reported. Of particular note the majority 
of the trials did not report the medical treatments, such as anti-platelet, lipid modifying, and anti-hypertensive 
medications, prescribed to participants and thus it was not possible to investigate if any variation in this may 
have impacted on the results.
In conclusion, this meta-analysis suggested that the three DMARD sub-classes tested did not significantly 
affect the risk of MACE. Further trials in people at high risk of cardiovascular events are needed before firm 
conclusions can be drawn.
Figure 5.  Effect of DMARDs on all-cause mortality.
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